Arax Advisory Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Arax Advisory Partners’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-323	Closed	-$6.92K	–	5216
2026 Q1	$6.92K	Buy	323 +311	+2,592%	+$4.38K	﹤0.01%	2639
2025 Q4	$112	Sell	12 -1,021	-99%	-$8.53K	﹤0.01%	3807
2025 Q3	$7.28K	Buy	+1,033	New	+$7.11K	﹤0.01%	2731
2024 Q4	–	Sell	-8	Closed	-$112	–	2502
2024 Q3	$112	Hold	8	–	–	﹤0.01%	2553
2024 Q2	$111	Buy	+8	New	+$117	﹤0.01%	2486

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Arax Advisory Partners's DAWN Position: Q2 2026 in Review

Arax Advisory Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 323 shares — an estimated $6.92K sold.

Arax Advisory Partners first reported a position in DAWN in Q2 2024 and held it in 5 quarters. The position peaked at $7.28K in Q3 2025. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Arax Advisory Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Arax Advisory Partners sold 323 Day One Biopharmaceuticals shares in Q2 2026, an estimated $6.92K.
Arax Advisory Partners first reported a position in Day One Biopharmaceuticals in Q2 2024 and held it in 5 quarters.
Arax Advisory Partners's Day One Biopharmaceuticals position peaked at $7.28K in Q3 2025.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.